Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBTH17 Cells May Serve as Biomarker in Metastatic Melanoma. By Morgan Bayer. September 28th 2024. TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.
LUNG CANCER - Targeted Oncology
WEBZipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC. Kristie L. Kahl. September 14th 2024. Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
About Us - Targeted Oncology
WEBAbout Us. Through our digital and print media platforms, Targeted Healthcare Communications offers a dedicated website and publication as well as a number of multichannel programs focused on precision medicine in oncology. Targeted Therapies in Oncology is dedicated to providing oncology healthcare …
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Bladder Cancer - Targeted Oncology
WEBFDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ. Jordyn Sava. April 22nd 2024. Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
MULTIPLE MYELOMA - Targeted Oncology
WEBDaratumumab and Lenalidomide Combo Boosts MRD-Negative Rates Multiple Myeloma. Ashling Wahner. September 27th 2024. Maintenance therapy with daratumumab and lenalidomide led to higher MRD-negative conversion rates compared to lenalidomide alone in newly diagnosed multiple myeloma patients following transplant.
AML - Targeted Oncology
WEBCell Therapies Emerge for the Treatment of Acute Myeloid Leukemia. Sabrina Serani. April 26th 2024. Cellular therapies are an effective option in hematologic malignancies but have been slower to develop in AML, but identifying new …
Targeted Therapies in Oncology - Targeted Oncology
WEBDecember 1, 2022. Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with its meeting coverage, columns, FDA news, and more. Click Here to Subscribe.
Targeted Publications
WEBPeers & Perspectives® in Oncology delivers exclusive coverage of virtual and in-person live events held by Targeted Oncology and Healthcare Research & Analytics®, thought leader collaborations, and community input on the growing targeted therapy space to encourage peer-informed decision-making in various disease states.. Featuring candid conversations among community and academic oncologists ...
Mantle Cell Lymphoma - Targeted Oncology
WEBFDA Approves Ready-to-Use Subcutaneous Bortezomib Formulation. By Sabrina Serani. September 6th 2024. The ready-to-use formulation of bortezomib is now an FDA-approved option for patients with multiple myeloma and mantle cell lymphoma. Frontline Acalabrutinib/BR Regimen Improves PFS in MCL. By Gina Mauro.